AGENUS INC Labor and Related Expense
AGENUS INC (AGEN) reported Labor and Related Expense of $4.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LaborAndRelatedExpense · last filed 2026-08-07
- AGENUS INC labor and related expense for the quarter ending 2026-06-30 was $4.14M, a 63.49% decline year-over-year.
- AGENUS INC labor and related expense for the quarter ending 2026-03-31 was $6.89M, a 43.04% decline year-over-year.
- AGENUS INC labor and related expense for the quarter ending 2025-12-31 was $6.94M, a 51.33% decline year-over-year.
- AGENUS INC labor and related expense for the quarter ending 2025-09-30 was $9.29M, a 39.19% decline year-over-year.
- AGENUS INC labor and related expense for fiscal 2025 was $39.66M, a 35.83% decline from fiscal 2024.
- AGENUS INC labor and related expense for fiscal 2024 was $61.81M, a 18.62% decline from fiscal 2023.
- AGENUS INC labor and related expense for fiscal 2023 was $75.95M, a 8.22% increase from fiscal 2022.
- AGENUS INC labor and related expense for fiscal 2022 was $70.19M.
| Period end | Labor and Related Expense 3 month | Labor and Related Expense 6 month | Labor and Related Expense 9 month | Labor and Related Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.14M 10-Q · filed 2026-08-07 | $11.03M 10-Q · filed 2026-08-07 | $17.97M derived: sum of 3 quarters · filed 2026-08-07 | $27.27M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $6.89M 10-Q · filed 2026-05-11 | $13.84M derived: sum of 2 quarters · filed 2026-05-11 | $23.13M derived: sum of 3 quarters · filed 2026-05-11 | $34.46M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $6.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $16.23M derived: sum of 2 quarters · filed 2026-03-16 | $27.56M derived: sum of 3 quarters · filed 2026-08-07 | $39.66M 10-K · filed 2026-03-16 |
| 2025-09-30 | $9.29M 10-Q · filed 2025-11-10 | $20.62M derived: sum of 2 quarters · filed 2026-08-07 | $32.72M 10-Q · filed 2025-11-10 | $46.99M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $11.33M 10-Q · filed 2026-08-07 | $23.43M 10-Q · filed 2026-08-07 | $37.69M derived: sum of 3 quarters · filed 2026-08-07 | $52.98M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $12.11M 10-Q · filed 2026-05-11 | $26.37M derived: sum of 2 quarters · filed 2026-05-11 | $41.65M derived: sum of 3 quarters · filed 2026-05-11 | $56.52M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $14.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $29.54M derived: sum of 2 quarters · filed 2026-03-16 | $44.41M derived: sum of 3 quarters · filed 2026-03-16 | $61.81M 10-K · filed 2026-03-16 |
| 2024-09-30 | $15.28M 10-Q · filed 2025-11-10 | $30.15M derived: sum of 2 quarters · filed 2025-11-10 | $47.55M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $14.87M 10-Q · filed 2025-08-11 | $32.27M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $17.40M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $75.95M 10-K · filed 2026-03-16 | |||
| 2022-12-31 | $70.19M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |